

Pharmacogenetics Testing in Psychiatry/Depression Market To Surpass USD 2,133.49 Mn by 2029

Pharmacogenetics Testing in Psychiatry/Depression Market To Progress at a CAGR of 9.5% and Surpass USD 2,133.49 Mn by 2029


PUNE, MAHARASHTRA, INDIA,
December 27, 2022 /

EINPresswire.com/ -- Data Bridge Market Research has recently published a research report titled, "[Pharmacogenetics Testing in Psychiatry/Depression Report](#), History and Forecast 2022-2029, Breakdown

Data by Key Players, Key Regions, Types and Application" assessing numerous factors impacting its trajectory. The Pharmacogenetics Testing in Psychiatry/Depression market report gives in-depth insights, Challenges, Growth and Upcoming developments about the industry. All composed market statistics data is verified and legal by industry specialists for readers and end users. The report evaluates the Pharmacogenetics Testing in Psychiatry/Depression market over the historical pricing structure, and trends that make it easy to predict growth momentum and precisely estimate the opportunities in the Pharmacogenetics Testing in Psychiatry/Depression Market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market.

Request for a free sample copy of this Pharmacogenetics Testing in Psychiatry/Depression Market Report at: <https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharmacogenetic-testing-in-psychiatry-depression-market>

Data Bridge Market Research analyzes that the global pharmacogenetics testing in psychiatry/depression market is expected to reach the value of USD 2,133.49 million by 2029, at a CAGR of 9.5% during the forecast period. Anxiety accounts for the largest type segment in the market due to the increasing depression rate among the global population. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.



Pharmacogenetics Testing in Psychiatry/Depression Market Competitive Outlook

Acquisitions, partnerships, and collaborations were among the market's inorganic growth strategies. As a result of these activities, Pharmacogenetics Testing in Psychiatry/Depression market participants have been able to increase their clientele and earnings.

Some of the major players operating in the global pharmacogenetics testing in psychiatry/depression market are

Genelex (Part of Invitae corporation)

Genewiz (Part of Azenta Life Sciences)

MD Labs

BiogeneiQ, Inc.

ONEOME, LLC

Myriad Genetics, Inc.

GenXys

Castle Biosciences, Inc.

PacBio

QIAGEN

Thermo Fisher Scientific Inc.

AB-Biotics.S.A.

Coriell Life Sciences

Eurofins Scientific

Illumina, Inc.

Dynamic DNA Laboratories

STADAPHARM GmbH

Color Health, Inc.

Cnsdose

Genomind, Inc.

Healthspek

myDNA Life Australia Pty Ltd.

HudsonAlpha

Sonic Healthcare Limited

Depression is a common illness worldwide, with an estimated 3.8% of the population affected, including 5.0% among adults and 5.7% among adults older than 60 years. Depression can become a serious health condition of mild to extreme severity, affecting the person to suffer greatly and can lead to suicide in the worst cases. Although over 45 antidepressants are available, suboptimal response poses a challenge and is considered a result of genetic variation, psychiatry/depression. Depending on the severity and pattern of depressive episodes over time, healthcare providers may offer psychological diagnosis such as behavioral activation, cognitive behavioral therapy, interpersonal psychotherapy, and/or antidepressant medication such as

selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs). Different drugs are used for this kind of mental disorder.

Pharmacogenetics Testing in Psychiatry/Depression Market Segmentation:

The market research observes a number of significant segments and sub-segments based on requirement, application, end users, and geography to acquire an understanding of the market.

Global pharmacogenetics testing in psychiatry/depression market is segmented into type, test type, gene type, patient type, product, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Global Pharmacogenetics Testing In Psychiatry/Depression Market, By Type

Anxiety

Mood Disorders

Depression

Bipolar Disorders

Psychotic Disorders

Eating Disorders

On the basis of type, global pharmacogenetics testing in psychiatry/depression market is segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, and eating disorders.

Global Pharmacogenetics Testing In Psychiatry/Depression Market, By Test Type

Whole Genome Sequencing

Chromosomal Array-Based Tests

On the basis of test type, global pharmacogenetics testing in psychiatry/depression market is segmented into whole genome sequencing, and chromosomal array-based tests.

Global Pharmacogenetics Testing In Psychiatry/Depression Market, By Gene Type

CYP2C19

CYP2C9 AND VKORC1

CYP2D6

HLA-B

HTR2A/C

HLA-A

CYP3A4

SLC6A4

MTHFR

COMT

OTHERS

On the basis of gene type, global pharmacogenetics testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9, VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and others.

Global Pharmacogenetics Testing In Psychiatry/Depression Market, By Patient Type

Child

Adult

Geriatric

On the basis of patient type, the global pharmacogenetics testing in psychiatry/depression market is segmented into children, adults, and geriatrics.

Global Pharmacogenetics Testing In Psychiatry/Depression Market, By Product

Instruments

Consumable

Software & Services

On the basis of product type, global pharmacogenetics testing in psychiatry/depression market is segmented into instruments, consumables, and software & services.

Global Pharmacogenetics Testing In Psychiatry/Depression Market, By End User

Hospitals & Clinics

Diagnostics Laboratories

Academic And Research Institutes

Others

On the basis of end user, global pharmacogenetics testing in psychiatry/depression market is segmented into hospitals and clinics, diagnostics laboratories, academic and research institutes, and others.

Global Pharmacogenetics Testing in Psychiatry/Depression Market, By Distribution Channel

Direct Tender

Third-Party Distribution

Hospital Pharmacy

Others

On the basis of distribution channel, the global pharmacogenetics testing in psychiatry/depression market is segmented into direct tender, third-party distribution hospital pharmacies, and others.

Do Read Whole Report Summary of the Pharmacogenetics Testing in Psychiatry/Depression Market at: <https://www.databridgemarketresearch.com/reports/global-pharmacogenetic-testing->

Pharmacogenetics Testing in Psychiatry/Depression Market Study and Strategies Carry Out as below:

The report contains a detailed assessment of major industry players operating in the Pharmacogenetics Testing in Psychiatry/Depression Market.

It covers latest development strategies, value chain analysis, and key growth prospects accepted by crucial manufacturers of the market.

It studies growth-oriented micro and macro-economic indicators.

Assessment of recent Pharmacogenetics Testing in Psychiatry/Depression market size, forecast information, and technology improvements within the industry

The research describes current information influencing the strategic scenario and imminent industry trends in the Pharmacogenetics Testing in Psychiatry/Depression Market.

This report estimates the market size and its contribution to the parent market

Assessment of Pharmacogenetics Testing in Psychiatry/Depression market Factor Analysis
Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis

2022-2029 Latest Updated Research Report with Overview, Definition, TOC, Market Key Players Update

The report includes top market players updated in 2022-2029 with their latest business strategy, sales volume and revenue analysis

North America is dominating the market. The increasing investment in R&D and increasing adoption of pharmacogenetics testing as an option for formulating treatment regimens is expected to boost the market growth. The U.S. dominates the North American region due to the strong presence of advanced technology providers such as Eurofins Scientific, Illumina, Inc., and others. The U.K. dominates Europe due to the increasing demand from emerging markets and the expansion of pharmaceutical industries. China dominates the Asia-Pacific region due to increased healthcare expenditure.

Pharmacogenetics test aids the medical professional in choosing the best medicine for the person because the test searches for the gene variant that may be responsible for influencing the effect of the drug.

Medicine is becoming personal, and patients gradually express interest in improved outcomes and less adverse effects with personalized medications. Personalized medicine has the potential to tailor the therapy with a high safety margin and the best response. This trend is largely driven by genome sequencing improvements.

Advances in pharmacogenomics have introduced an increasing number of opportunities to bring personalized medicine into clinical practice for psychiatric disorders. Personalized medicine may be defined as a comprehensive, prospective approach to preventing, diagnosing, treating, and monitoring disease in ways that achieve optimal individual health care decisions. Over 100

medications now contain United States Food and Drug Administration (FDA) labelling related to potentially applicable pharmacogenomic biomarkers with technological advancements in healthcare. Also, new and advanced methods are being developed to promote pharmacogenetics testing in depression-like disorders. These tests use advanced genetic testing methods to give precise results to form a treatment regimen. The improvements in technology supporting tests improved accessibility of testing options, and the growing number of resources that help clinicians understand how to use this information when it is available are making this aspect of personalized or precision medicine a reality. Thus, providers need to become more aware of the scientific and clinical relevance of pharmacogenomic tests.

Table of Contents:

1 INTRODUCTION
2 MARKET SEGMENTATION
3 EXECUTIVE SUMMARY
4 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, REGULATIONS
5 MARKET OVERVIEW
6 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE
7 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PRODUCT
8 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TEST TYPE
9 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENE TYPE
10 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY PATIENT TYPE
11 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET , BY END USER
12 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL
13 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY REGION
14 GLOBAL PHARMACOGENETICS TESTING IN PSYCHIATRY/DEPRESSION MARKET: COMPANY LANDSCAPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
17 QUESTIONNAIRE
18 RELATED REPORTS

Get Access to the Complete TOC for Pharmacogenetics Testing in Psychiatry/Depression Market here: <https://www.databridgemarketresearch.com/toc/?dbmr=global-pharmacogenetic-testing-in-psychiatry-depression-market>

What does this Report provide?

How the Pharmacogenetics Testing in Psychiatry/Depression market is evolving?

What is driving and restraining Pharmacogenetics Testing in Psychiatry/Depression dynamics?

How will each Pharmacogenetics Testing in Psychiatry/Depression's submarket will segment

grow over the forecast period and how much sales will these submarkets account for in 2029?

How will market shares of each of the Pharmacogenetics Testing in Psychiatry/Depression submarkets develop from 2022 to 2029?

Which Pharmacogenetics Testing in Psychiatry/Depression submarket will be the main driver of the overall market from 2022 to 2029?

How will political regulatory factors influence regional Pharmacogenetics Testing in Psychiatry/Depression markets and submarkets?

Who are the leading players and what are the prospects over the forecast period?

What are the moving and arising advances expected to influence the [advancement of the Pharmacogenetics Testing in Psychiatry/Depression market](#)?

The research includes historical data from 2018 to 2022 and forecasts until 2029, which offerings the report openly for industry executives, marketing, sales and product managers looking for key industry data in simply accessible documents; It is a appreciated resource for consultants, analysts and stakeholders. Tables and graphs

Related Reports:

Global Heart Valve Devices Market <https://www.databridgemarketresearch.com/reports/global-heart-valve-devices-market>

Europe Heart Valve Devices Market <https://www.databridgemarketresearch.com/reports/europe-heart-valve-devices-market>

Asia-Pacific Heart Valve Devices Market
<https://www.databridgemarketresearch.com/reports/asia-pacific-heart-valve-devices-market>

Middle East and Africa Heart Valve Devices Market
<https://www.databridgemarketresearch.com/reports/middle-east-and-africa-heart-valve-devices-market>

North America Heart Valve Devices Market
<https://www.databridgemarketresearch.com/reports/north-america-heart-valve-devices-market>

Browse Our Other Trending Reports:

Global Musculoskeletal (MSK) Disease Management Market
<https://www.databridgemarketresearch.com/reports/global-musculoskeletal-msk-disease-management-market>

Europe Musculoskeletal (MSK) Disease Management Market
<https://www.databridgemarketresearch.com/reports/europe-musculoskeletal-msk-disease-management-market>

Asia-Pacific Musculoskeletal (MSK) Disease Management Market

<https://www.databridgemarketresearch.com/reports/asia-pacific-musculoskeletal-msk-disease-management-market>

Middle East and Africa Musculoskeletal (MSK) Disease Management Market

<https://www.databridgemarketresearch.com/reports/middle-east-and-africa-musculoskeletal-msk-disease-management-market>

North America Musculoskeletal (MSK) Disease Management Market

<https://www.databridgemarketresearch.com/reports/north-america-musculoskeletal-msk-disease-management-market>

About Data Bridge Market Research, Private Ltd

Data Bridge Market Research Pvt Ltd is a multinational management consulting firm with offices in India and Canada. As an innovative and neoteric market analysis and advisory company with unmatched durability level and advanced approaches. We are committed to uncover the best consumer prospects and to foster useful knowledge for your company to succeed in the market.

Data Bridge Market Research is a result of sheer wisdom and practice that was conceived and built-in Pune in the year 2015. The company came into existence from the healthcare department with far fewer employees intending to cover the whole market while providing the best class analysis. Later, the company widened its departments, as well as expands their reach by opening a new office in Gurugram location in the year 2018, where a team of highly qualified personnel joins hands for the growth of the company. "Even in the tough times of COVID-19 where the Virus slowed down everything around the world, the dedicated Team of Data Bridge Market Research worked round the clock to provide quality and support to our client base, which also tells about the excellence in our sleeve."

Sopan Gedam

Data Bridge Market Research

+ +1 888-387-2818

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/608333918>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.